Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -1-
July 22, 2002
- SSP Aims at 5.7% Sales Rise in Self-Medication Division
July 22, 2002
- BUSINESS NEWS IN BRIEF -2-
July 22, 2002
- MEDICAL DEVICE NEWS IN BRIEF
July 22, 2002
- NEW PRODUCTS
July 22, 2002
- Roche Diagnostics Starts Mouse DNA Chip Consortium
July 22, 2002
- Korosho to Draft Guidelines for Physician-led Clinical Trials
July 22, 2002
- Otsuka Transfers Contract Lab Test Business to BML
July 22, 2002
- Korosho to Set Examples in Reform
July 22, 2002
- GL for Treatment of Esophageal Cancer Prepared
July 22, 2002
- REGULATORY NEWS IN BRIEF
July 22, 2002
- Shortage of Pharmacists Unlikely: Korosho Survey
July 22, 2002
- Aiming to Become Agile, Nimble Innovative Drug Firm: Mr Kannan of Allergan
July 22, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 22, 2002
- Kyowa Hakko Pharma Business to Focus on Cancer, Allergy
July 22, 2002
- 11 of 15 Major Firms Introduce Researchers Rewarding Programs: Survey
July 22, 2002
- Nippon Kayaku Licensed Paclitaxel DDS from NanoCarrier
July 22, 2002
- Korosho Panel Recommends GLs for Infertility Therapy
July 22, 2002
- Fujisawa Licenses Cefzon to Xian-Janssen in China
July 22, 2002
- GL to Include MNZ in Secondary H. pylori Eradication Therapy
July 22, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…